Ciara Kennedy Net Worth

Ciara Kennedy biography

Dr. Ciara Kennedy Ph.D. serves as Independent Director of the Company. Since December 2016, Dr. Kennedy has served as President, Chief Executive Officer and director of Amplyx Pharmaceuticals, and previously served as the company’s Chief Operating Officer beginning in October 2015. Amplyx is a clinical-stage company developing innovative drug therapies for debilitating and life-threatening diseases in patients with compromised immune systems. Prior to Amplyx, she served as Chief Operating Officer at Lumena Pharmaceuticals, until the company’s acquisition by Shire Pharmaceuticals, and then continued as Vice President, Head of Cholestatic Liver Disease at Shire post acquisition. Previously, Dr. Kennedy held several positions at Cypress Bioscience where she played a key role in the company’s FDA approval and launch of Savella® for fibromyalgia, and also held several positions in program and alliance management at Biogen Idec where she managed multiple development projects spanning the drug discovery and development continuum. She is a founder of Reneo Pharmaceuticals and Mirum Pharmaceuticals, and also serves as a director of privately held Aristea Therapeutics. Dr. Kennedy received her doctorate at the Queen’s University of Belfast, Northern Ireland, her Master of Business Administration from the Rady School of Management at University of California, San Diego, and her Bachelor of Science from University College Cork, Ireland.

How old is Ciara Kennedy?

Ciara Kennedy is 48, he's been the Independent Director of Otonomy Inc since 2020. There are 12 older and 1 younger executives at Otonomy Inc. The oldest executive at Otonomy Inc is James Breitmeyer, 66, who is the Independent Director.

What's Ciara Kennedy's mailing address?

Ciara's mailing address filed with the SEC is C/O OTONOMY, INC., 4796 EXECUTIVE DRIVE, SAN DIEGO, CA, 92121.

Insiders trading at Otonomy Inc

Over the last 10 years, insiders at Otonomy Inc have traded over $30,282,796 worth of Otonomy Inc stock and bought 755,065 units worth $12,114,945 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Holdings A/S Novo, and Brian H Dovey. On average, Otonomy Inc executives and independent directors trade stock every 66 days with the average trade being worth of $7,317. The most recent stock trade was executed by Vickie L Capps on 28 November 2022, trading 42,242 units of OTIC stock currently worth $4,224.

What does Otonomy Inc do?

Otonomy is a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. The company pioneered the application of drug delivery technology to the ear in order to develop products that achieve sustained drug exposure from a single local administration. This approach is covered by a broad patent estate and is being utilized to develop a pipeline of products addressing important unmet medical needs including Ménière's disease, hearing loss, and tinnitus.

Otonomy Inc executives and stock owners

Otonomy Inc executives and other stock owners filed with the SEC include:

• David Weber,
  President, Chief Executive Officer, Director
• Dr. David Allen Weber,
  Pres, CEO & Director
• Paul Cayer,
  Chief Financial and Business Officer
• Robert Savel,
  Chief Technical Officer
• Paul E. Cayer,
  Chief Financial & Bus. Officer
• Robert Michael Savel II,
  Chief Technical Officer
• Jay Lichter,
  Independent Chairman of the Board
• Vickie Capps,
  Independent Director
• Iain McGill,
  Independent Director
• James Breitmeyer,
  Independent Director
• Theodore Schroeder,
  Independent Director
• Dr. Jay B. Lichter Ph.D.,
  Co-Founder & Independent Chairman
• Ciara Kennedy,
  Independent Director
• James Branch CPA,
  VP of Fin. & Controller
• David Skarinsky,
  Sr. VP of Clinical
• Breianna Bowen,
  VP of HR
• Fabrice Piu Ph.D.,
  Sr. VP of Preclinical Devel.
• Barbara M. Finn,
  Sr. VP of Regulatory Affairs & Quality Assurance
• Dr. Alan Charles Foster Ph.D.,
  Chief Scientific Officer
• Julie D. Burgess,
  VP of Fin. & Admin.
• Dr. Rick Adam Friedman M.D., Ph.D.,
  Co-Founder and Member of the Advisory Panel
• Dr. Allen F. Ryan Ph.D.,
  Co-Founder and Member of the Advisory Panel
• Katherine Mary Bishop,
  Chief Scientific Officer
• Eric J Loumeau,
  GC & Chief Compliance Officer
• Carl Le Bel,
  Chief Scientific Officer
• Heather Preston,
  Director
• George J Morrow,
  Director
• Advisors Llc Orbi Med Capit...,
  
• Chau Quang Khuong,
  Director
• Anthony J Yost,
  Chief Commercial Officer
• Dean Hakanson,
  Chief Medical Officer
• John P Mckearn,
  Director
• Partners Viii, L.P.Blair Ja...,
  
• Ventures Viii Lp Avalon Ven...,
  
• Holdings A/S Novo,
  10% owner
• Group Holdings (Sbs) Adviso...,
  
• Viii Associates, L.P.Domain...,
  
• Alan Charles Foster,
  Chief Scientific Officer
• Brian H Dovey,
  Director
• Jill Marie Broadfoot,
  Director